Compare Synchrony Financial (SYF) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs Spyre Therapeutics Inc. Common Stock — how do they compare? Synchrony Financial trades at $71.41 (market cap $23.94B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Synchrony Financial is far larger — about 3.2× Spyre Therapeutics Inc. Common Stock's market cap, and Synchrony Financial pays a 1.85% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Synchrony Financial for 30 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SYF | SYRE | |
|---|---|---|
Market Cap | $23.94B | $7.52B |
Volume | 2,618,932 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $88.47 | $108.92 |
52-Week Low | $63.78 | $22.18 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $24.18B | $6.52B |
Dividend Yield | 1.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $73.59, down slightly by 0.04% on the day. The stock exhibits a bullish technical signal overall, with support near $73 and resistance at $75. Fundamentally, the company shows strong profitability with a 23.4% net income margin and a compelling valuation at a P/E of 7.55. Recent earnings have consistently beaten expectations, and strategic partnerships, like the one with OpenAI announced on August 17, 2026, highlight growth initiatives.
The outlook for SYF is positive, supported by robust analyst sentiment with a consensus price target of $87.50, implying significant upside. Key opportunities include high ROE and strategic expansions in digital finance. Risks involve potential consumer credit deterioration, as noted in broader market news on August 26, 2026, and increased investing cash outflows in 2026, which could pressure near-term liquidity.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
